Benzinga | Oct 13, 2021 01:38PM EDT

Stifel Maintains Hold on CRISPR Therapeutics, Lowers Price Target to $101

Stifel analyst Benjamin Burnett maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Hold and lowers the price target from $139 to $101.